Oxford University tests smart glasses for low vision

Article

Researchers at Oxford University are developing smart glasses to help individuals with limited vision navigate the world around them.

Oxfordshire, UK-Researchers at Oxford University are developing smart glassesto help individuals with limited vision navigate the world around them.

Google Glass: The next frontier?

The smart glasses consist of a video camera mounted on the frame of the glasses; a pocket-sized computer unit; and software that provides images of near-by objects to a see-through display on the lenses of the glasses. The aim is not to replace lost vision but to assist users with spatial awareness, allowing them to see obstacles in their path.

Researchers say they would like to eventually have a product that looks like a regular pair of eyeglasses and would not cost more than a few hundred pounds.

“The idea of the smart glasses is to give people with poor vision an aid that boosts their awareness of what's around-allowing greater freedom, independence, and confidence to get about, and a much improved quality of life,” says Stephen Hicks, PhD, of the Nuffield Department of Clinical Neurosciences at the University of Oxford, who is leading the development of the glasses. 

Researchers plan to test the device with 30 volunteers with poor vision. 

Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.